azaserine and Carcinoma-in-Situ

Previous studies in our laboratory demonstrated that pancreatic carcinomas in rodents express receptors for the peptide hormone gastrin that are not present in normal adult pancreas. In view of an abundant literature suggesting that gastrin may promote growth of various gastrointestinal tissues and tumors, the effect of hypergastrinemia on the process of pancreatic carcinogenesis was evaluated.. Rats received subcutaneous injections of the pancreatic carcinogen azaserine at 19 and 26 days of age. Starting at 12 months of age, animals were randomized to treatment with the proton pump inhibitor lansoprazole or vehicle by gavage for 6 months. At autopsy, pancreatic wet weight normalized to body weight was recorded, as well as the number of benign and malignant pancreatic lesions.. Serum gastrin levels were determined by radioimmunoassay and showed a greater than two-fold increase in lansoprazole-treated animals. Pancreatic wet weight in hypergastrinemic rats was increased compared to controls (p <0.05). Premalignant lesions such as acidophilic atypical acinar cell foci, adenomas, heterogeneous phenotypic populations of nodules within nodules, and carcinoma-in-situ were not increased in the hypergastrinemic group. Likewise, there was no difference in the incidence of invasive carcinoma in hypergastrinemic animals (10%) compared to controls (5.7%).. Hypergastrinemia stimulated an increase in pancreatic weight, but did not stimulate development of premalignant lesions or progression to cancer in the azaserine model of rat pancreatic acinar cell carcinoma.

Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Animals; Anti-Ulcer Agents; Azaserine; Carcinoma in Situ; Carcinoma, Acinar Cell; Disease Models, Animal; Gastrins; Lansoprazole; Male; Omeprazole; Organ Size; Pancreas; Pancreatic Neoplasms; Precancerous Conditions; Rats; Rats, Inbred Lew

The ubiquitin (Ub)-proteasome proteolytic system is highly selective, and the specific proteins involved in cell division, growth, activation, signaling and transcription are degraded at different rate depending on the physio-pathological state of the cell. Ubiquitination serves first of all as a signal for protein degradation of short-lived and abnormal proteins under several stressful conditions. The immunocytochemical localization of Ub in some malignant tumours has recently been presented and differences in Ub expression has been observed during malignant transformation. Change in the level of Ub and Ub-conjugated proteins might reflect a higher metabolic-catabolic ratio in neoplastic cells. Most studies have been focused on the malignant stage of tumour progression, and only a few papers have dealt with the change in Ub and Ub-protein conjugates level during the whole progression. To address this problem, we applied an azaserine-induced pancreatic carcinogenesis model, in which premalignant and malignant stages were investigated throughout the progression. The level of Ub immunoreactivity was measured in nucleus and cytoplasm by electron microscopic immunocytochemical and morphometrical methods. We found a significant increase of Ub level in the nucleus and the cytoplasmic area in premalignant atypical acinar cell nodule (AACN) cells and in malignant adenocarcinoma in situ (CIS) cells at month 20 after initiation.

Topics: Adenocarcinoma; Adenoma; Animals; Azaserine; Carcinoma in Situ; Cell Nucleus; Cysteine Endopeptidases; Cytoplasm; Immunohistochemistry; Male; Multienzyme Complexes; Neoplasm Proteins; Pancreatic Neoplasms; Precancerous Conditions; Proteasome Endopeptidase Complex; Rats; Rats, Wistar; Ubiquitin

Growth regulation is a crucial event in tumour progression. Surprisingly, relatively few papers have dealt with the catabolic side of regulation, and there are practically no data regarding the autophagic process during tumour development. We approach this problem by morphometrical investigation into the possible changes of autophagic activity during the progression of rat pancreatic adenocarcinoma induced by azaserine. In the present study, autophagic capacity of the azaserine-induced premalignant and malignant cells were characterised and compared to the respective host tissue cells of the rat pancreas and to the acinar cells in other stages of tumour development. Using vinblastine (VBL) as an enhancer, and cycloheximide (CHI) as an inhibitor of autophagic segregation we observed that autophagic capacity of premalignant cells (month 6 and 10 after initiation) is much higher than in the host tissue cells. We found a sharp decrease in self-digesting capacity in adenocarcinoma cells (month 20) where VBL induced a minimal accumulation of autophagic vacuoles which was, surprisingly, not inhibited by CHI, i.e. the CHI-sensitive regulatory step was lost. The changes in autophagic capacity are probably associated to specific steps of tumour progression in our system.

Topics: Adenocarcinoma; Adenoma; Animals; Autophagy; Azaserine; Carcinoma in Situ; Cycloheximide; Male; Pancreatic Neoplasms; Rats; Rats, Wistar; Time Factors; Vinblastine

Studies were undertaken to characterize the growth of the azaserine-induced putative preneoplastic lesions in rats and to determine if a single dose of azaserine would be carcinogenic. Male Lewis rats were given a single i.p. injection of 30 mg L-azaserine/kg body weight at 7 weeks of age. A purified diet was fed throughout the study. Rats (10-12 per group) were autopsied at 6, 9, 12, 15 and 18 months post-initiation, and pancreases were quantitatively evaluated to characterize the growth of acidophilic and basophilic foci and nodules (henceforth called foci), and the incidence of neoplasms. All azaserine-treated rats had foci, and at all times approximately equal numbers of acidophilic and basophilic foci were present in the pancreas. The number of basophilic foci increased with time, and while their size also increased, the change was small compared with the increase in size of the acidophilic foci. Conversely, all acidophilic foci appeared to be present by 6-9 months, and their size greatly increased with time. The data suggest that virtually all foci persist rather than regress or remodel. At 9 months the incidence of carcinoma in situ was 30% and by 18 months there was a 100% incidence of pancreatic cancers (58% carcinoma in situ and 42% carcinoma).

Topics: Animals; Azaserine; Carcinoma; Carcinoma in Situ; Male; Pancreas; Pancreatic Neoplasms; Precancerous Conditions; Rats; Rats, Inbred Lew